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Background: Development of tumour resistance to chemotherapeutic drugs and concerns over their toxic
effects has led to the increased use of medicinal herbs or natural products by cancer patients. Strobilanthes
crispus is a traditional remedy for many ailments including cancer. Its purported anticancer effects have led to the
commercialization of the plant leaves as medicinal herbal tea, although the scientific basis for its use has not
been established. We previously reported that a bioactive subfraction of Strobilanthes crispus leaves (SCS) exhibit
potent cytotoxic activity against human breast cancer cell lines. The current study investigates the effect of this
subfraction on cell death activities induced by the antiestrogen drug, tamoxifen, in estrogen receptor-responsive
and nonresponsive breast cancer cells.
Methods: Cytotoxic activity of SCS and tamoxifen in MCF-7 and MDA-MB-231 human breast cancer cells was determined
using lactate dehydrogenase release assay and synergism was evaluated using the CalcuSyn software. Apoptosis
was quantified by flow cytometry following Annexin V and propidium iodide staining. Cells were also stained with
JC-1 dye to determine changes in the mitochondrial membrane potential. Fluorescence imaging using FAM-FLICA
assay detects caspase-8 and caspase-9 activities. DNA damage in the non-malignant breast epithelial cell line,
MCF-10A, was evaluated using Comet assay.
Results: The combined SCS and tamoxifen treatment displayed strong synergistic inhibition of MCF-7 and MDA-MB-231
cell growth at low doses of the antiestrogen. SCS further promoted the tamoxifen-induced apoptosis that was associated
with modulation of mitochondrial membrane potential and activation of caspase-8 and caspase-9, suggesting the
involvement of intrinsic and extrinsic signaling pathways. Interestingly, the non-malignant MCF-10A cells displayed
no cytotoxicity or DNA damage when treated with either SCS or SCS-tamoxifen combination.
Conclusions: The combined use of SCS and lower tamoxifen dose could potentially reduce the side effects/toxicity
of the drug. However, further studies are needed to determine the effectiveness and safety of the combination
treatment in vivo.
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Tamoxifen is the gold standard hormonal therapy for
estrogen receptor-positive (ER+) breast cancers by acting
as an estrogen antagonist on breast tissue [1]. It is also
used as adjuvant therapy for breast cancer to reduce the
risk of recurrence [2]. However, about half of these
cancers do not respond to tamoxifen. Another important
drawback of the drug is its reduced efficacy with long-
term use, as most tumours eventually develop resistance
to tamoxifen [3,4]. In addition, adverse side effects in-
cluding uterine cancer and thromboembolic disease have
been attributed to the use of tamoxifen [1]. In fact,
concerns over toxicity of chemotherapeutic drugs have
primarily contributed to the increased use of herbal and
natural products for cancer treatment [5]. The combined
use of natural products and conventional anticancer
drugs is believed to enhance the efficacy of anticancer
treatment due to their potential additive or synergistic
effects. Furthermore, such combination treatment could
potentially reduce the side effects of chemotherapy.
However, such purported advantages of natural products
have not been scientifically established.
The flowering shrub, Strobilanthes crispus (Acanthacea)
is traditionally used as a folklore medicinal plant in
Malaysia and Indonesia. Its leaves have been traditionally
used to treat various ailments including breast and uterine
cancers and gastrointestinal and kidney diseases [6,7]. The
plant is locally known as ‘pecah beling’ or ‘kecibeling’ in
Indonesia and ‘pecah kaca’ or ‘jin batu’ by the Malays, or
as ‘bayam karang’ by the Orang Asli tribe in Malaysia. The
leaves of this plant taken orally, is believed to enhance the
immune system [8]. The plant is also known as Hei Mian
Jiang Jun (Black-faced General) to the local Chinese com-
munity and the leaves of the plants are normally boiled
and taken as tea or is mixed with other herbs. Based on its
traditional use, the plant is also commercialised as tea and
dehydrated herb, and recommended for those with cancer
and other ailments. Its consumption as herbal tea also
provides additional antioxidants such as catechins [9]. The
water extract of S. crispus contains compounds that
could block the proliferation of retroviruses in T-cell
leukemia by attaching to the active sites of reverse
transcriptase [10]. Cytotoxicity against liver, colon and
breast cancer cell lines [11] and chemopreventive effects
of S. crispus extract against rodent hepatocellular car-
cinoma [12] have been reported. Findings from our
research group showed that a bioactive subfraction of S.
crispus extract induced apoptosis of breast and prostate
cancer cells [13]. The current study further investigates
the cellular anticancer activities of an S. crispus subfraction
(SCS) and its ability to modulate tamoxifen-induced effects
on the breast cancer cell lines, MCF-7 and MDA-MB-231,
as well as the non-cancerous breast epithelial cell line,
MCF-10A.Methods
Chemicals
Dulbecco modified Eagle’s medium (DMEM), Ham F12-K
medium, Rosselle’s Park Memorial Institute medium
(RPMI-1640) and penicillin/streptomycin/glutamine (100×)
were purchased from GIBCO BRL (UK). Fetal bovine
serum (FBS) and trypsin/EDTA were purchased from
Hyclone (USA) and BDH Chemicals (UK), respectively.
Dimethyl sulphoxide (DMSO), hydrogen peroxide (H2O2)
and tamoxifen were purchased from Sigma-Aldrich
(USA). Phosphate buffered saline (PBS) was purchased
from Amresco (USA). All chemicals used in the experi-
ments were of analytical grade.
Plant material
The S. crispus plants were collected from Tasek Gelugor,
Pulau Pinang, Malaysia and authenticated by Mr
Baharuddin Sulaiman, a taxonomist at the School of
Biological Sciences, Universiti Sains Malaysia. A voucher
specimen of the plant (no. 11046), was then prepared and
deposited at the herbarium of the School of Biological
Sciences [13].
Cell culture and treatment
MCF-7 and MDA-MB-231 cells (American Type Culture
Collection, Rockville, USA) were grown in RPMI-1640
and Dulbecco’s modified Eagle’s medium (DMEM), re-
spectively, supplemented with 10% fetal bovine serum
(Hyclone, USA) and 100 units/ml penicillin. MCF-10A
cells were maintained in DMEM/F12 complete growth
medium. All cells were maintained at 37°C in a humidi-
fied condition with 5% CO2. Prior to treatment, the cul-
ture medium was replaced with medium supplemented
with 2% fetal bovine serum. Tamoxifen (Sigma Aldrich,
USA) was freshly diluted in the culture medium for each
experiment. The SCS was prepared as previously re-
ported (previously coded as SC/D-F9) [13] and stored as
crystalline solids at −80°C until use.
Determination of cytotoxic effects and combination index
MCF-7 and MDA-MB-231 cells were seeded in 24-well
plates (Corning, Baxter Scientific, McGaw Park, IL) at
100,000 cells per ml, allowed to attach overnight and
treated with SCS (8.5 and 15.0 μg/ml [13]), tamoxifen
(2.5-15 μM) or their combination for up to 48 h at 37°C.
Control cells received the vehicle, dimethyl sulfoxide
(<0.1%). The cytotoxic effect was determined using
lactate dehydrogenase (LDH)-release assay (Roche
Diagnostics, Mannheim, Germany) as described by the
manufacturer. The combined effect of SCS and tam-
oxifen was then analysed using the CalcuSyn software
using non-constant ratio combination design (Biosoft,
UK). All tests were performed in triplicates.
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Apoptotic or necrotic cell death was quantified by flow
cytometry using the fluorescein isothiocyanate (FITC)-
labelled annexin V and propidium iodide (PI) (Annexin-
V-FLUOS Staining Kit [Roche, Germany]) according to
the manufacturer’s recommendations. Cell nuclei were
stained with Hoechst dye. Cells were harvested after
24 and 48 h incubation with SCS and tamoxifen by
using 0.02% trypsin-EDTA, pelleted by centrifugation
at 1,000 rpm and washed in phosphate buffered saline.
A minimum of 10,000 events were collected and analysed
using the FACS Calibur instrument and CellQuest Pro
software (Becton Dickinson, USA).Assessment of changes in the mitochondrial membrane
potential
Changes in the mitochondrial membrane potential
(ΔΨm) were determined quantitatively by flow cy-
tometry, using 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-
benzimidazolylcarbocyanine iodide (JC-1) dye (Invitrogen,
USA) at 24 and 48 h post-treatment according to the
manufacturer’s instructions. JC-1 accumulates within the
intact mitochondria to form multimer J-aggregates that
resulted in a change of fluorescence from red to green
indicating decreased ΔΨm. The green and red fluorescence
was estimated in FL1 and FL2 channel, respectively, using
a minimum of 10,000 events. The percentage of cells with
green fluorescence (JC-1 monomers) which represent
depolarized cells was measured.Assessment of caspase 8 and caspase 9 activities
Cells were cultured on chamber slides and treated with
SCS and tamoxifen for 24 h. FAM-FLICA™ Caspase-8
and FAM-FLICA™ Caspase-9 Assay kits (Immunochemistry
Technologies) were used to detect caspase 8 and caspase 9
activation in the cells, respectively. This methodology is
based on the use of non-cytotoxic and cell-permeable
fluorochrome inhibitor of caspases (FLICA) that binds
covalently to active caspases and emits green fluorescence.
Cells with activated caspase 8 or caspase 9 were observed
using the fluorescence microscope according to the manu-
facturer’s guidelines.Assessment of DNA damage
MCF-10A cells cultured in 25 cm2 flasks were treated
with SCS (8.5 μg/ml) and tamoxifen (5 μM) alone or in
combination for 24 h. DMSO (0.1%) was used as a
vehicle control and hydrogen peroxide (H2O2) was used
as a positive control (20 min incubation). DNA damage
was evaluated using the Comet assay (Trevigen, USA)
following the manufacturer’s instructions.Statistical analyses
At least three independent experiments were carried
out. Significant differences in the mean values were
calculated by one-way analysis of variance (ANOVA)
followed by post hoc Tukey multiple comparison test using
IBM® SPSS® Statistics 20 (United States) for Windows and
considered statistically significant at p < 0.05.
Results
Synergistic cytotoxicity of SCS and tamoxifen
Tamoxifen showed a dose-dependent cytotoxicity on
MCF-7 and MDA-MB-231 cells (Figure 1). At 24 h,
about 60% and 90% cell death were recorded with
15 μM tamoxifen, respectively. Efficacy of treatment was
increased with the combination of SCS and tamoxifen
compared to either single agent. The presence of SCS
(8.5 μg/ml or 10.0 μg/ml) further increased the percent-
age of cell death induced by tamoxifen in both cell lines.
When given alone, no significant cell death was recorded
with tamoxifen treatment at the low concentrations of
2.5 and 5 μM in MCF-7 cells but 90% cell death was re-
corded with the combined treatment of tamoxifen at
these concentrations and SCS after 24 h (p <0.001).
Similar cell death promoting effect was observed in
MDA-MB-231 cells with 85% and 95% cell death ob-
tained with 2.5 and 5 μM tamoxifen and SCS com-
bination at 24 h (p < 0.001). The promoting effect of
SCS was time-dependent as well as tamoxifen dose-
dependent in both cell lines and could be observed as
early as 12 h post treatment. Maximum cell death was
achieved with all combined treatment groups at 48 h.
Dose-effect analysis of the combination treatment was
carried out based on the method of Chou-Talalay and
the type of interaction between the two agents was eval-
uated using the combination index (CI) [14,15]. Accord-
ing to this method, synergism is indicated by a CI of less
than 1, additivity by a CI equal to 1, and antagonism
by a CI greater than 1. Normalised isobolograms con-
structed for non-constant ratio drug combinations
(Figure 2) display data points below the additivity line,
indicating strong synergy in growth inhibition of MCF-7
and MDA-MB-231 cells by SCS (8.5 μg/ml or 10.0 μg/ml)
and tamoxifen (2.5 to 15 μM) combination. The calculated
CI values obtained were 0.32 – 0.40 for MCF-7 cells and
0.29 – 0.52 for MDA-MB-231 cells at 84 – 97% fractions
affected. Since SCS is found to significantly promote the
growth-inhibitory effect of tamoxifen at low doses, 2.5
and 5 μM tamoxifen were therefore used for subsequent
treatments.
Promotion of tamoxifen-induced apoptosis by SCS
Phosphatidylserine is translocated from the inner mem-
brane to the outer layer during early stages of apoptosis
and could be detected using the phospholipid-binding
Figure 1 Enhancement of tamoxifen-induced cytotoxicity in breast cancer cell lines by SCS. Percentage of cell death following treatment
with DMSO (control); SCS (8.5 and 10.0 μg/ml for MCF-7 and MDA-MB-231 cells, respectively); 2.5, 5.0, 10.0 and 15.0 μM tamoxifen (T2.5-T15); and
their combination with SCS (C2.5-C15) was determined at 6, 12, 24 and 48 h using the LDH assay. Data shown are the mean values ± SD from
three independent experiments. Statistical analyses was determined using one-way ANOVA followed by post hoc Tukey multiple comparison test
with *p < 0.05, **p < 0.01, ***p < 0.001, significantly different from control; ap < 0.05, bp < 0.01, cp < 0.001, combination treatment compared
to tamoxifen.
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could discriminate between apoptotic and necrotic cells.
We have previously shown that SCS is capable of indu-
cing apoptosis. Here, flow cytometric analysis showed
that the combination of SCS and tamoxifen resulted in
promotion of apoptosis with a significant increase in
late-stage apoptosis of MCF-7 cells compared to either
treatment alone (p < 0.001; Figure 3). The combination
of 2.5 μM tamoxifen and SCS caused 55% late apoptosis
after 24 h treatment which increased to 88% at 48 h,
resulting in total apoptosis of 63% and 92%, respectively.
On the other hand, only 27% and 40% apoptosis was
seen with tamoxifen alone at 24 h and 48 h, respectively.
The combination of 5.0 μM tamoxifen and SCS resulted
in 92% and 98% total apoptosis at 24 h and 48 h,
respectively. Not more than 2% necrotic cells were
observed with all treatments.About 11% apoptotic MDA-MB-231 cells were observed
following treatment with 2.5 μM tamoxifen while 5.0 μM
tamoxifen induced up to 25% apoptosis (Figure 4). The
percentage of cell death increased significantly with co-
administration of SCS (p < 0.001). Total apoptosis of
68% - 84% was recorded with 2.5 μM tamoxifen-SCS
combination and more than 90% with 5.0 μM tamoxifen-
SCS combination. The induction of apoptosis was time-
and dose-dependent in both cells and the 4 to 9-fold
increase in the number of cells at late stage apoptosis
indicates that SCS not only promoted apoptotic cell
death but also enhanced the rate of apoptosis.
Enhancement of mitochondrial membrane depolarization
by SCS and tamoxifen
A decrease in the Δψm is considered as one of the


















Figure 2 Dose-effect analysis and the combination effect of tamoxifen and SCS. Dose-effect analysis was performed using 8.5-12.5 μg/ml
SCS and 2.5-15 μM tamoxifen, for 24 h. Dose-effect curve of each agent alone for MCF-7 cells (A) and MDA-MB-231 cells (C) is representative of
three independent experiments. EC50 concentrations of SCS and 2.5-15 μM tamoxifen were used for combination effect analysis using the CalcuSyn
program and normalized isobolograms for MCF-7 (B) and MDA-MB-231 (D) cells are shown. Diagonal line is the additivity line and data points below
this line correspond to a synergistic effect. The concentration ratios between SCS and tamoxifen are indicated below the isobologram.
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depolarization in both MCF-7 (50% at 24 h [p < 0.01]; 69%
at 48 h [p < 0.001]) and MDA-MB-231 (77% at 24 h; 89%
at 48 h [both p < 0.001]) cells. On the other hand, 2.5 μM
tamoxifen had no significant effect while 5.0 μM tam-
oxifen produced 30 to 35% depolarized MCF-7 cells
(Figure 5). Enhanced alteration in the Δψm occured in
the presence of both tamoxifen and SCS compared to
tamoxifen alone (p < 0.001) whereby the combination
treatment caused up to 90% cells to be depolarized.
Significantly higher percentages of MDA-MB-231 cells
were also depolarized when treated with both tamoxifen
and SCS compared to tamoxifen alone (p < 0.001) but
these were attributed to the potent effect of SCS itself
(Figure 6). These results suggest the involvement of the
mitochondrial pathway in SCS-induced cell death either
alone or in combination with tamoxifen in both cell lines.
SCS and tamoxifen activate caspase 8 and caspase 9
Prior work by our group demonstrated that SCS acti-
vated the effector caspase 3/7 in both MCF-7 and MDA-
MB-231 cells [13]. In the current study, we observed
that the initiator caspases 8 and 9 were also stronglyactivated by SCS in both cell lines as indicated by in-
tense green fluorescence signal that directly reflects the
amount of caspase activity in the cells (Figures 7 and 8).
Tamoxifen on the other hand, activated these caspases
in a smaller population of MCF-7 and MDA-MB-231
cells. When these cells were co-treated with both agents,
high activation of both caspases was observed.
Cytotoxic acitivity and DNA damage in non-cancerous
MCF10A cells
Since SCS could promote the effects of tamoxifen on
MCF-7 and MDA-MB-231 cells, we investigated
whether a similar response would occur in the non-
cancerous breast epithelial cells, MCF-10A. A small but
insignificant increase in the percentage of cell death was
observed with 5.0 μM tamoxifen treatment compared to
untreated cells, while 15 μM tamoxifen was found to be
highly cytotoxic (Figure 9). SCS however, was not cyto-
toxic to the cells and did not significantly modulate
tamoxifen-induced cytotoxicity, unlike the observations
with the cancer cells above. In addition, analysis using
the Comet assay (also called single cell gel electro-
phoresis) further showed that the DNA integrity of
Figure 3 Promotion of tamoxifen-induced apoptosis of MCF-7 cells by SCS. Cells were treated with 8.5 μg/ml SCS and 2.5 (Tam2.5) or 5.0 μM
tamoxifen (Tam5) alone and in combination for 24 and 48 h. Harvested cells were incubated with annexin-V antibody and PI dye and analysed by flow
cytometry. (A) Quadrant location for the representative dot plots: lower left – negative immunofluorescence (living cells); lower right – annexin
V positive (early apoptosis); upper left – PI positive (necrosis), upper right – annexin V and PI positive (late apoptosis). (B) Each bar represents
mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 significantly different from control; cp < 0.001 SCS + Tam vs
Tam alone (one-way ANOVA and post hoc Tukey multiple comparison test).
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ment (Figure 10). Cells with damaged DNA would
display DNA comet tails that consist of single-stranded or
double-stranded DNA breaks. Tamoxifen (5.0 μM) treat-
ment showed the presence of some DNA damage with a
few comet tails detected and the presence of SCS did not
significantly modulate the tamoxifen effect. Exposure of
MCF-10A cells to H2O2 showed extensive DNA damage.
Discussion
The S. crispus plant has been traditionally used since
time immemorial and has been of much interest due to
traditional claims of its anticancer properties [6]. Its
widespread use is evidenced by its reference in the publi-
cation of the Indonesian pharmaceutical regulatory agency
[7]. Based on our previous findings of apoptotic cell death
induced by a bioactive subfraction of the plant, SCS, the
present study was carried out to examine possible syner-
gistic interaction between SCS and tamoxifen in inhibiting
growth and inducing death of breast cancer cells. Import-
antly, evaluation on the non-cancerous breast epithelial
cell line, MCF-10A, was also performed to provide add-
itional information on the potential use of this natural
product in the clinical setting.Tamoxifen is a partial agonist of ER, blocking the pro-
liferative effects of estrogen via this receptor. It causes
growth arrest at nanomolar concentrations but cell
death at micromolar concentrations [16]. In the current
study, 2.5 to 15.0 μM tamoxifen were tested on MCF-7
and MDA-MB-231 cells. Clinically relevant steady-state
plasma concentrations of tamoxifen and its metabolites
can be close to 5 μM in the patient sera [17] and 5 – 11
times higher in intratumoral tissues such as the mam-
mary gland [18]. Thus the concentrations used in this
study are within the range achievable in human plasma.
Combination therapy offers the advantage of possible
dose reduction via synergistic growth inhibition of can-
cerous cells with potential reduction in toxicity caused
by the chemotherapeutic agent. We demonstrated for
the first time that a subfraction of S. crispus synergistic-
ally promoted tamoxifen-induced cytotoxicty of breast
cancer cells. Induction of cell death was time- and dose-
dependent, with near maximum cell death achieved when
combined with 2.5 μM tamoxifen, suggesting the potential
of using a lower tamoxifen dose to achieve the same level
of effectiveness as demonstrated by a high tamoxifen dose
alone. This may supposedly also reduce the toxicity and
perhaps inhibit the development of resistance to this drug.
Figure 4 Promotion of tamoxifen-induced apoptosis of MDA-MB-231 cells by SCS. Cells were treated with 10.0 μg/ml SCS and 2.5 (Tam2.5)
or 5.0 μM tamoxifen (Tam5) alone and in combination for 24 and 48 h. Harvested cells were incubated with Annexin-V antibody and PI dye and
analysed by flow cytometry. (A) Quadrant location for the representative dot plots: lower left – negative immunofluorescence (living cells); lower
right – annexin V positive (early apoptosis); upper left – PI positive (necrosis), upper right – annexin V and PI positive (late apoptosis). (B) Each bar
represents mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 significantly different from control; cp < 0.001 SCS + Tam vs
Tam alone (one-way ANOVA and post hoc Tukey multiple comparison test).
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apoptosis induced by tamoxifen in both MCF-7 and
MDA-MB-231 cell lines. Similar levels of apoptosis were
achieved when SCS was combined with either 2.5 μM or
5.0 μM tamoxifen after 48 h exposure, further indicating
that SCS synergises with tamoxifen to achieve efficacy at
lower drug concentrations in both cell lines. In addition,
SCS enhanced the rate of apoptosis in both cell lines
with higher percentages of cells in late stage apoptosis
compared to tamoxifen alone. It is noteworthy that
tamoxifen induced a lower percentage of apoptosis in
MDA-MB-231 cells compared to MCF-7 cells which is
consistent with the findings of Kallio et al. [19] who
reported a slower death rate in the ERα-negative cells
by this drug.Mitochondrial dysfunction is considered as an early
event in the apoptotic cascade, characterised by an
increase in membrane permeability and loss of ΔΨm
(reviewed in [20]). Mitochondria of cancer cells display
higher ΔΨm [21] and chemotherapeutic agents induce
mitochondrial membrane permeabilization resulting in
the collapse of ΔΨm [22]. In the present study, tamoxifen-
induced apoptosis of MCF-7 and MDA-MB-231 cells was
accompanied by dose-dependent depolarization of the
mitochondrial membrane, similar to earlier findings [19].
SCS seems to be more potent in promoting membrane
permeabilization in these cells. Further depolarization of
the mitochondrial membrane occurred when SCS was
combined with tamoxifen. Kallio et al. [19] reported 7 μM
as the threshold concentration of tamoxifen needed to
Figure 5 Depolarization of the mitochondrial membrane of MCF-7 cells by SCS alone and in combination with tamoxifen. MCF-7 cells
treated with 8.5 μg/ml SCS and 2.5 (Tam2.5) or 5.0 μM tamoxifen (Tam5) alone and in combination for 24 and 48 h were incubated with the JC-1
dye and analysed by flow cytometry. (A) Representative dot plots: J-aggregated red fluorescence (polarized cells); JC-1 monomer green fluorescence
(depolarized cells). (B) Each bar represents mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 significantly different from
control; cp < 0.001 SCS + Tam vs Tam alone (one-way ANOVA and post hoc Tukey multiple comparison test).
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80% or more reduction in the ΔΨm of MCF-7 cells is
achieved with only 2.5 μM tamoxifen in the presence of
SCS, indicating the ability of SCS to sensitize the cancer
cells to mitochondrial membrane disruption. Similar ef-
fects were noted in MDA-MB-231 cells suggesting an
ERα-independent action. Loss of mitochondrial mem-
brane potential would lead to cytochrome c release from
the intermembrane compartment of mitochondria to the
cytosol [23].
Caspases are responsible, in part, for the cellular
changes during apoptosis. They are synthesised as zymo-
gens (procaspases) that are activated by proteolytic
cleavage and can cleave many cellular substrates in regu-
lating apoptosis [24]. Intrinsic and extrinsic pathways
are two established mechanisms for caspase-dependentapoptosis. The intrinsic pathway transduces cell death
signals via the mitochondrial system while the extrinsic
pathway involves ligand binding to death receptor com-
plexes on cell surfaces. Both events involve activation
of initiator caspases, leading to cleavage and activation
of effector caspases to execute apoptotic cell death
(reviewed in [25]).
We previously demonstrated that SCS induced apop-
tosis of both MCF-7 and MDA-MB-231 cells by activat-
ing the executioner caspase-3/7 [13]. MCF-7 cells are
functionally deficient of caspase-3 [26] and thus, effector
caspase-7 mediates apoptosis of these cells [27]. Here we
show that SCS strongly activates initiator caspase-8 in
both cells while tamoxifen did not significantly activate
it in MCF-7 cells. Caspase-8 plays a role in the extrinsic
apoptosis pathway and is activated following stimulation
Figure 6 Depolarization of the mitochondrial membrane of MDA-MB-231 cells by SCS alone and in combination with tamoxifen.
MDA-MB-231 cells treated with 10.0 μg/ml SCS and 2.5 (Tam2.5) or 5.0 μM tamoxifen (Tam5) alone and in combination for 24 and 48 h were incubated
with the JC-1 dye and analysed by flow cytometry. (A) Representative dot plots: J-aggregated red fluorescence (polarized cells); JC-1 monomer green
fluorescence (depolarized cells). (B) Each bar represents mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 significantly
different from control; cp < 0.001 SCS + Tam vs Tam alone (one-way ANOVA and post hoc Tukey multiple comparison test).
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tumour necrosis factor-related (TNFR) death receptors
or activation of their corresponding ligands. This leads
to the formation of death-inducing signalling complex
(DISC) resulting in proteolytic activation of procaspase-
3/7 [25]. Stimulation with chemotherapeutic agents are
reported to cause caspase-8 activation which directly
activates caspase-3 [22,28] or in the case of MCF-7 cells,
caspase 7, leading to apoptosis. We observed that co-
treatment of both MCF-7 and MDA-MB-231 cells with
tamoxifen and SCS caused strong activation of caspase-
8, in line with the synergistic cytotoxic effect and the
promotion of apoptotic cell death above. This could be
contributed by the presence of β-sitosterol, one of the
identified components of S. crispus [11], reported to in-
duce apoptosis of MDA-MB-231 cells [29] and increasecaspase-8 activity in MCF-7 and MDA-MB-231 cells in
association with elevation of Fas protein expression [30].
Alternatively, caspase-8 cleaves BH3-only protein, Bid,
to generate the truncated form of Bid, t-Bid [31]. Trans-
location of t-Bid to the mitochondrial outer membrane
promotes the release of cytochrome c that binds to
Apaf-1 adaptor protein to form apoptosome with the
recruitment and activation of caspase-9, a key initiator
caspase of the intrinsic pathway. Activation of caspase-9
following caspase-8 activation has been reported, leading
to the activation of the effector caspase-3 [32]. Although
a previous study did not show caspase-9 cleavage in
MCF-7 cells [19], we observed some caspase-9 activity
in both MCF-7 and MDA-MB-231 cells with similar
concentrations of tamoxifen. Interestingly, SCS strongly




Figure 7 Activation of caspase 8 in MCF-7 and MDA-MB-231 cells by SCS alone and in combination with tamoxifen. Cells were stained
with FLICA™ FAM-VAD-FMK for detection of active caspase-8 and labeled with PI and Hoescht stain following treatment with SCS (8.5 and 10.0 μg/ml
for MCF-7 and MDA-MB-231 cells, respectively), tamoxifen (5.0 μM) or their combination for 24 h. Caspase-FLICA stains active caspases green; PI stains




Figure 8 Activation of caspase 9 in MCF-7 and MDA-MB-231 cells by SCS alone and in combination with tamoxifen. Cells were stained with
FLICA™ FAM-VAD-FMK for detection of active caspase-9 and labeled with PI and Hoescht stain following treatment with SCS (8.5 and 10.0 μg/ml for
MCF-7 and MDA-MB-231 cells, respectively), tamoxifen (5.0 μM) or their combination for 24 h. Caspase-FLICA stains active caspases green; PI stains
dead or dying cells red; Hoescht stains the nuclei of all cells blue.
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Figure 9 Cytotoxic effects of SCS alone and in combination with tamoxifen on MCF-10A cells. Cytotoxicity was measured at 24, 48 and 72 h of
treatment with SCS (8.5 μg/ml), tamoxifen (5 and 15 μM) and their combination using the LDH assay. DMSO was used as a vehicle control. Data
shown are the mean values ± SD from three independent experiments. Statistical analysis was determined using one-way ANOVA followed by
post hoc Tukey multiple comparison test with *p < 0.05 and ***p < 0.001 compared to control.
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http://www.biomedcentral.com/1472-6882/14/252cells either alone or in the presence of tamoxifen, indi-
cating that the SCS is also capable of stimulating the
intrinsic pathway of apoptosis. In agreement to this,
a recent study reported that S. crispus ethanol extract
increased caspase-9 concentration and induced cytosolic
translocation of cytochrome c in MCF-7 cells [33].Control (DMSO 0.1%)
SCS (EC50)
Tam (5 µM)
SCS  + Tam
Hydrogen peroxide 
     (100 µM)
100X
Figure 10 Effect of SCS alone and in combination with tamoxifen on
(8.5 μg/ml), tamoxifen (15 μM) and their combination for 24 h and stain
Assay. H2O2 (100 μM) was used as the positive control. The micrographs show
damaged DNA display comet tails while undamaged DNA will appear as intaOther studies have also reported enhanced activities
of chemotherapeutic drugs by plant-derived products.
Examples include the synergistic inhibition of HT-29
colon cancer cell growth by the chemotherapeutic drug
5-fluorouracil (5-FU) and genistein (soy flavone) com-
bination, which involves upregulation of pro-apoptotic200X
the DNA integrity of MCF-10A cells. Cells were treated with SCS
ed with SYBR Green for evaluation of DNA damage using the Comet
images of DNA captured under fluorescence microscopy. Cells with
ct DNA head.
Yaacob et al. BMC Complementary and Alternative Medicine 2014, 14:252 Page 12 of 13
http://www.biomedcentral.com/1472-6882/14/252p53 and p21 [34]. Gambogic acid (a component of resin
from Garcinia hanburryi tree) is also able to enhance
the sensitivity of BGC-823 gastric carcinoma cells to
5-FU by regulating key enzymes in the 5-FU metabolic
pathway [35]. Recently, curcumin (yellow pigment of
turmeric), which acts as an inhibitor of cyclooxygenase-
2 was demonstrated to enhance the growth inhibitor
effects of 5-FU on HT-29 cells [36].
Studies on the combination of tamoxifen with other
agents such as TRAIL [37] and rapamycin [38] have
been reported to produce synergistic apoptotic activity.
However, the therapeutic potential of TRAIL for ex-
ample, is limited by concerns over its potential hepato-
toxicity [39,40]. Tamoxifen itself was found to be more
cytotoxic to normal cells compared to cancerous cells
[41]. This was thought to be due to higher expression of
ER in the normal cells. Unlike tamoxifen, SCS is non-
cytotoxic to the non-cancerous MCF-10A cells [13]. In
addition, contrary to our observation with the breast
cancer cells above, SCS does not potentiate the cytotoxic
effect of tamoxifen on MCF-10A cells. SCS also does not
promote DNA damage either as a single agent or in
combination with tamoxifen. This is an important obser-
vation since tamoxifen is capable of forming DNA ad-
ducts in treated women [42,43]. Tamoxifen treatment of
breast cancer patients or as a chemopreventive agent
has in fact been associated with increased risk of endo-
metrial cancer [44,45] thought to be due to its estrogenic
activity on the endometrium via ER or as a result of
tamoxifen-DNA adduct formation [46].
Conclusion
An exciting outcome from this study is the observation
that SCS synergized the cytotoxic action of tamoxifen at
sub-optimal doses of the drug not only in ERα-positive
MCF-7 but also in the ERα-negative MDA-MB-231 cells.
The fact that we can use sub-optimal doses of tamoxifen
to achieve the desired cytotoxic effect suggests the po-
tential for reduction in side effects/toxicity as observed
on non-cancerous cells (as depicted in MCF-10A). The
possibility of SCS to act via a mechanism independent of
ER thus provides the opportunity to target multiple can-
cer signaling pathways when combined with the anti-
estrogen. Although cell death is controlled by multiple
inputs, the mitochondria play a central role in its major
pathway and our findings show enhancement of apop-
tosis via perturbation of mitochondrial function and
activation of caspases in both intrinsic and extrinsic
pathways. The mechanism is likely to be dependent on
transcriptional regulation of apoptotic signaling proteins.
Investigation on the contribution of these signaling pro-
teins and the potential of SCS to overcome or prevent
resistance to tamoxifen can be the focus of future stud-
ies. The presence of multiple compounds in naturalproducts such as SCS can provide the advantage of act-
ing on multiple pathways that control the process of
cancer development and progression. The potential of
the S. crispus subfraction is thus to be exploited for
improvement of therapeutic responses and perhaps the
reduction in drug toxicity in cancer therapy.
Abbreviations
SCS: Strobilanthes crispus subfraction; ER: Estrogen receptor; LDH: Lactate




The authors declare that they have no competing interests.
Authors’ contributions
NSY conceived and designed the study, interpreted the data and prepared
the manuscript. NNNMK performed the experimental work, prepared and
analysed the data and participated in the preparation of the manuscript.
MNN participated in the study design and preparation of the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The authors thank Professor V. Navaratnam and Raihana Hamzah of the
Center for Drug Research, Universiti Sains Malaysia, for providing the natural
product material.
Author details
1Department of Chemical Pathology, School of Medical Sciences, Universiti
Sains Malaysia Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia.
2School of Health Sciences, Universiti Sains Malaysia Health Campus, 16150
Kubang Kerian, Kelantan, Malaysia.
Received: 12 April 2014 Accepted: 11 July 2014
Published: 18 July 2014
References
1. Bush NJ: Advances in hormonal therapy for breast cancer. Semin Oncol
Nurs 2007, 23:46–54.
2. Kudachadkar R, O’Regan RM: Aromatase inhibitors as adjuvant therapy for
postmenopausal patients with early stage breast cancer. CA Cancer J Clin
2005, 55:145–163.
3. Muss HB: Endocrine therapy for advanced breast cancer: a review. Breast
Cancer Res Treat 1992, 21:15–26.
4. Riggins RB, Bouton AH, Liu MC, Clarke R: Antiestrogens, aromatase
inhibitors, and apoptosis in breast cancer. Vitam Horm 2005, 71:201–237.
5. Chen XW, Sneed KB, Zhou SF: Pharmacokinetic profiles of anticancer
herbal medicines in humans and the clinical implications. Curr Med Chem
2011, 18:3190–3210.
6. Goh KL: Malaysian Herbs. Klang: Goh Kong Ling; 2004:249.
7. Sunarto PA: Materia Medica Indonesia. 1st edition. Jakarta: Penerbitan
Directorat Jenderal Pengawasan Obat dan Makanan; 2007:95–99.
8. Samuel AJS, Kalusalingam A, Chellappan DK, Gopinath R, Radhamani S,
Husain A, Murugananadham V, Promiwichit P: Ethnomedical survey of
plants used by the Orang Asli in Kampung Bawong, Perak, West
Malaysia. J Ethnobiol Ethnomed 2010, 6:5.
9. Ismail M, Manickam E, Md Danial A, Rahmat A, Yahaya A: Chemical
composition and antioxidant activity of Strobilanthes crispus leaf. J Nut
Biochem 2000, 11:536–542.
10. Kusumoto IT, Shimada I, Kakiuchi N, Hattori M, Namba T, Supriyatna S:
Inhibitory effects of Indonesian plant extracts on reverse transcriptase of
an RNA tumour virus (I). Phytother Res 1992, 6:241–244.
11. Rahmat A, Edrini S, Ismail P, Yun Hin TY, Abu Bakar MF: Chemical constituents,
antioxidant activity and cytotoxic effects of essential oil from Strobilanthes
crispus and Lawsonia inermis. J Biol Sci 2006, 6:1005–1010.
12. Jaksa S, Rahmat A, Othman F, Ismail P, Mansor SM: Effect of Strobilanthes
crispus on the histology and tumour marker enzymes in rat liver during
hepatocarcinogenesis. J Med Sci 2005, 5:130–135.
Yaacob et al. BMC Complementary and Alternative Medicine 2014, 14:252 Page 13 of 13
http://www.biomedcentral.com/1472-6882/14/25213. Yaacob NS, Hamzah N, Nik Mohamed Kamal NN, Zainal Abidin SA, Lai CS,
Navaratnam V, Norazmi MN: Anticancer activity of a subfraction of
dichloromethane extract of Strobilanthes crispus on human breast and
prostate cancer cells in vitro. BMC Complement Altern Med 2010, 10:42.
14. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the
combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme
Regul 1984, 22:27–55.
15. Chou TC: Theoretical basis, experimental design, and computerized
simulation of synergism and antagonism in drug combination studies.
Pharmacol Rev 2006, 58:621–681.
16. Mandlekar S, Kong AN: Mechanisms of tamoxifen-induced apoptosis.
Apoptosis 2001, 6:469–477.
17. Peyrade F, Frenay M, Etienne MC, Ruch F, Guillemare C, Francois E, Namer
M, Ferrero JM, Milano G: Age-related difference in tamoxifen disposition.
Clin Pharmacol Ther 1996, 59:401–410.
18. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson
C, Serrano D, Pelosi G, Decensi A, Lien EA: Tamoxifen and metabolite
concentrations in serum and breast cancer tissue during three dose
regimens in a randomized preoperative trial. Clin Cancer Res 2004,
10:2336–2343.
19. Kallio A, Zheng A, Dahllund J, Heiskanen KM, Härkönen P: Role of
mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer
cells. Apoptosis 2005, 10:1395–1410.
20. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol
2007, 35:495–516.
21. Chen LB: Mitochondrial membrane potential in living cells. Annu Rev Cell
Biol 1988, 4:155–181.
22. Debatin KM, Poncet D, Kroemer G: Chemotherapy: targeting the
mitochondrial cell death pathway. Oncogene 2002, 21:8786–8803.
23. Heiskanen KM, Bhat MB, Wang HW, Ma J, Nieminen AL: Mitochondrial
depolarization accompanies cytochrome c release during apoptosis in
PC6 cells. J Biol Chem 1999, 274:5654–5658.
24. Salvesen GS, Dixit VM: Caspases: intracellular signaling by proteolysis. Cell
1997, 91:443–446.
25. Rossi D, Gaidano G: Messengers of cell death: apoptotic signaling in
health and disease. Haematologica 2003, 88:212–218.
26. Jänicke RU, Sprengart ML, Wati MR, Porter AG: Caspase-3 is required for
DNA fragmentation and morphological changes associated with
apoptosis. J Biol Chem 1998, 273:9357–9360.
27. Hu C-CA, Tang C-HA, Wang J-J: Caspase activation in response to cytotoxic
Rana catesbeiana ribonuclease in MCF-7 cells. FEBS Lett 2001, 503:65–68.
28. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, Wajant H,
Jänicke RU, Porter AG, Belka C, Gregor M, Schulze-Osthoff K, Wesselborg S:
Caspase-8/FLICE functions as an executioner caspase in anticancer
drug-induced apoptosis. Oncogene 2000, 19:4563–4573.
29. Awad AB, Downie D, Fink CS: Inhibition of growth and stimulation of
apoptosis by beta-sitosterol treatment of MDA-MB-231 human breast
cancer cells in culture. Int J Mol Med 2000, 5:541–545.
30. Awad AB, Chinnam M, Fink CS, Bradford PG: β-Sitosterol activates Fas
signaling in human breast cancer cells. Phytomedicine 2007, 14:747–754.
31. Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase 8 mediates the
mitochondrial damage in the Fas pathway of apoptosis. Cell 1998,
94:491–501.
32. McDonnell MA, Wang D, Khan SM, Vander Heiden MG, Kelekar A: Caspase-9
is activated in a cytochrome c-independent manner early during TNFα-
induced apoptosis in murine cells. Cell Death Differ 2003, 10:1005–1015.
33. Chong HZ, Rahmat A, Yeap SK, Md Akim A, Alitheen NB, Othman F,
Gwendoline-Ee CL: In vitro cytotoxicity of Strobilanthes crispus ethanol
extract on hormone dependent human breast adenocarcinoma MCF-7
cell. BMC Complement Altern Med 2012, 12:35.
34. Hwang JT, Ha J, Park OJ: Combination of 5-fluorouracil and genistein
induces apoptosis synergistically in chemoresistant cells through the
modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res
Commun 2005, 332:433–440.
35. Wang J, Liu W, Zhao Q, Qi Q, Lu N, Yang Y, Nei F-F, Rong J-J, You Q-D, Guo Q-L:
Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human
gastric carcinoma. Toxicology 2009, 256:135–140.
36. Srimuangwong K, Tocharus C, Yoysungnoen CP, Suksamrarn A,
Tocharus J: Hexahydrocurcumin enhances inhibitory effect of
5-fluorouracil on HT-29 human colon cancer cells. World J
Gastroenterol 2012, 18:2383–2389.37. Lagadec C, Adriaenssens E, Toillom RA, Chopin V, Romon R, Van Coppenolle
F, Hondermarck H, Le Bourhis X: Tamoxifen and TRAIL synergistically
induce apoptosis in breast cancer cells. Oncogene 2008, 27:1472–1477.
38. de Graffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva
JM, Roth RA, Hidalgo M: Inhibition of mTOR activity restores tamoxifen
response in breast cancer cells with aberrant Akt activity. Clin Cancer Res
2004, 10:8059–8067.
39. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K: The kiss of death: promises
and failures of death receptors and ligands in cancer therapy. Leukemia
2001, 15:1022–1032.
40. Wajant H, Pfizenmaier K, Scheurich P: TNF-related apoptosis inducing
ligand (TRAIL) and its receptors in tumor surveillance and cancer
therapy. Apoptosis 2002, 7:449–459.
41. Petinari L, Kohn LK, de Carvalho JE, Genari SC: Cytotoxicity of tamoxifen in
normal and tumoral cell lines and its ability to induce cellular
transformation in vitro. Cell Biol Int 2004, 28:531–539.
42. Shibutani S, Suzuki N, Terashima I, Sugarman SM, Grollman AP, Pearl ML:
Tamoxifen-DNA adducts detected in the endometrium of women
treated with tamoxifen. Chem Res Toxicol 1999, 12:646–653.
43. Umemoto A, Monden Y, Lin CX, Momen A, Ueyama Y, Komaki K, Santosh L,
Shinya S: Determination of tamoxifen-DNA adducts in leukocytes from
breast cancer patients treated with tamoxifen. Chem Res Toxicol 2004,
17:1577–1583.
44. Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast
cancer: an overview of the randomized trials. Lancet 1998, 351:1451–1467.
45. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E,
Perlman JA, Ford L: Tamoxifen therapy for breast cancer and endometrial
cancer risk. J Natl Cancer Inst 1999, 91:1654–1662.
46. Kim SY, Suzuki N, Laxmi YR, Shibutani S: Genotoxic mechanism of tamoxifen
in developing endometrial cancer. Drug Metab Rev 2004, 36:199–218.
doi:10.1186/1472-6882-14-252
Cite this article as: Yaacob et al.: Synergistic anticancer effects of a
bioactive subfraction of Strobilanthes crispus and tamoxifen on MCF-7
and MDA-MB-231 human breast cancer cell lines. BMC Complementary
and Alternative Medicine 2014 14:252.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
